On the 19th, the document on centralized procurement of diclofenac and other drugs of Guangdong alliance was officially released, and blood products and recombinant human growth hormone were included in centralized collection for the first time. Once the news was released, several “flash collapses” were smashed in the secondary market. However, the reporter of science and Innovation Board daily learned that centralized collection not only has a limited impact on the blood products industry, but also may be good for .
According to the above-mentioned documents, 276 chemicals and therapeutic biological products are involved in this centralized collection, of which blood products specifically involve five varieties: intravenous injection of human immunoglobulin (pH4), human immunoglobulin, human coagulation factor VIII, human fibrinogen and human albumin.
In principle, the procurement cycle shall not exceed two years. The alliance areas participating in centralized mining include Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang and Xinjiang production and Construction Corps.
After the release of the document, the domestic growth hormone leader Changchun High And New Technology Industries (Group) Inc(000661) (000661. SZ) fell to the limit.
There was a sudden collapse in the afternoon of Hualan Biological Engineering Inc(002007) (002007. SZ), Beijing Tiantan Biological Products Corporation Limited(600161) (600161. SH), Shanghai Raas Blood Products Co.Ltd(002252) (002252. SZ), Boya Bio-Pharmaceutical Group Co.Ltd(300294) (300294. SZ) related to blood products, of which Hualan Biological Engineering Inc(002007) fell the most, down 5.63% as of the closing and 7.71% as of the intraday.
Boya Bio-Pharmaceutical Group Co.Ltd(300294) , Beijing Tiantan Biological Products Corporation Limited(600161) rebounded after a slight shock. As of the close, they fell slightly by 0.65% and 0.94% respectively.
” This may be an emotional panic in the market. At present, China’s blood products industry is in short supply. Generally speaking, the impact of centralized collection on the industry is limited, and may even be good. ” some people in the industry commented on the reporter of science and innovation board daily.
logic of centralized collection of blood products
Similar to the previous centralized purchase documents, the above-mentioned document also limits the “maximum price” that can be quoted by the reporting enterprise. However, in terms of blood products, the “ceiling price” of some varieties in the document is even higher than the previous bidding price, which is very rare in centralized collection .
For example, the highest valid bid price of 10G albumin, a common specification, is 601.8804 yuan, up 59% from the last bidding price of 378 yuan in Guangdong; The highest valid application price of Jingbing’s common specification of 2.5G is 917.5 yuan, 53% higher than the previous average price of 600 yuan.
Why is this “abnormal” situation? This may be determined by the supply and demand relationship of blood products themselves.
The aforementioned industry personage explained that “there is no way to ‘bring the quantity’ of blood products. From the perspective of supply and demand, China has already been in short supply.” Yan Ming analysts also believe that there is a long-term gap at the supply side of China’s blood products. In recent years, with the superposition of rapid demand growth and slow growth at the supply side, the gap at the supply side of China’s blood products is still accelerating.
It is reported that blood products take the plasma of healthy people as the raw material, which is a relatively scarce resource, and its supply is closely related to the number of plasma stations mastered by each company. Another person in the industry told the reporter of the science and Innovation Board daily that the new plasma station needs to be approved at the policy level, and the approval speed is not fast. Therefore, enterprises may be more than willing to “expand production capacity”.
In terms of data, in 2019, the plasma stations and plasma collection volumes in the United States were 805 and 55000 tons respectively, while those in China were 269 and 9200 tons. Moreover, among blood products, only albumin and recombinant coagulation factor products are allowed to be imported, and other blood products can only be produced by Chinese enterprises.
or intended to rectify the industry
After centralized collection, is the price of blood products increased or decreased? How much can it be?
The reporter of science and Innovation Board daily contacted Hualan Biological Engineering Inc(002007) , Beijing Tiantan Biological Products Corporation Limited(600161) , Boya Bio-Pharmaceutical Group Co.Ltd(300294) . All enterprises said that they had not reached the quotation stage, and they were actively studying countermeasures. at the same time, some enterprises further disclosed in the exchange that “centralized purchase is not expected to have a great impact on prices”, and others said that “centralized purchase has no impact on enterprises”.
From a comprehensive point of view, the centralized collection of blood products by Guangdong alliance may have a limited impact on the industry, whether in terms of “price” or “volume”.
At the same time, the above-mentioned industry insiders believe that the Guangdong alliance’s centralized collection of blood products this time, or for the consideration of re standardizing the industry and forming a reasonable market price, further, that is, squeezing out the “gray sales cost”. “from this point, it may be good for the leading enterprises of blood products.” The person believes that.
As for whether the centralized purchase will be launched nationwide, some enterprises believe that “Guangdong alliance may be a pilot, and the LAND-TO-LAND meeting will be launched”, while others believe that “it’s not good to say and can’t be predicted” in view of the particularity of blood products.
